Psoriasis injection okayed for limited use to treat COVID patients: Drug controller
Team Udayavani, Jul 11, 2020, 8:11 AM IST
Image for representation
New Delhi: India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for ‘restricted emergency use’ to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
‘The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome,” an official told PTI.
‘It is already an approved drug of Biocon for treating psoriasis for last many years,’ the official said.
Written informed consent of each patient is required before the use of this drug, he said.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Lok Sabha elections 2024: EC takes cognisance of MCC violation by Modi, Rahul; seeks response by April 29
Lok Sabha polls 2024: Sunita Kejriwal likely to join AAP’s campaign in Delhi, will hold roadshows this weekend
Kerala Election 2021: 194 Candidates Battle for Votes from 2.75 Crore Voters
Accused in firing on police arrested in Delhi’s Rohini
Rahul Gandhi concludes Maharashtra visit, departs for Delhi
MUST WATCH
Latest Additions
Kollegela MLA A.R. Krishnamurthy escapes unhurt in car mishap
Lok Sabha elections 2024: EC takes cognisance of MCC violation by Modi, Rahul; seeks response by April 29
Polali: Case filed against a man for molesting minor
Kotak Mahindra Bank shares tank 13%; mcap erodes by Rs 37,721 crore post RBI action
Lok Sabha polls 2024: Sunita Kejriwal likely to join AAP’s campaign in Delhi, will hold roadshows this weekend